Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ono Pharmaceutical CoOPHLF 79 Return-on-Tangible-Asset is 0.46% as of Mar. 2026, which is 95% below its 10-year median of 10.18. GuruFocus rates OPHLF with a GF Score™ of 79/100 and a GF Value™ of $12.82 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Ono Pharmaceutical Co ranks better than 78.55% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Ono Pharmaceutical Co's annualizedNet Income for the quarter that ended in Mar. 2026 was $21 Mil. Ono Pharmaceutical Co's average total tangible assets for the quarter that ended in Mar. 2026 was $4,524 Mil. Therefore, Ono Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 0.46%.
The historical rank and industry rank for Ono Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
OPHLF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.38 Med: 10.18 Max: 15.33
Current: 10.1
During the past 13 years, Ono Pharmaceutical Co's highest Return-on-Tangible-Asset was 15.33%. The lowest was 6.38%. And the median was 10.18%.
OPHLF's Return-on-Tangible-Asset is ranked better than 78.55% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs OPHLF: 10.10
Ono Pharmaceutical Co (OTCPK:OPHLF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Ono Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Ono Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Ono Pharmaceutical Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ono Pharmaceutical Co Return-on-Tangible-Asset Chart
OPHLF vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ono Pharmaceutical Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Ono Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.46% mean?
Ono Pharmaceutical Co (OPHLF) has a Return-on-Tangible-Asset of 0.46% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ono Pharmaceutical Co and its competitors. This is 95% below median its historical median of 10.18. Over the past decade, Ono Pharmaceutical Co's Return-on-Tangible-Asset has ranged from 6.38 to 15.33. According to the industry distribution chart, Ono Pharmaceutical Co ranks #216 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 21.4%.
Is Ono Pharmaceutical Co's Return-on-Tangible-Asset too high?
Ono Pharmaceutical Co's current Return-on-Tangible-Asset of 0.46% is 95% below median its 10-year median of 10.18. Over the past 10 years, this metric has ranged from a low of 6.38 to a high of 15.33. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Ono Pharmaceutical Co's value of 0.46% is 85.4% below this industry median. Based on the distribution chart, Ono Pharmaceutical Co ranks #216 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ono Pharmaceutical Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Ono Pharmaceutical Co ranks #216 out of 1007 companies for Return-on-Tangible-Asset. This places Ono Pharmaceutical Co in the top 21% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. Ono Pharmaceutical Co's value of 0.46% is 85.4% below this benchmark. Historically, Ono Pharmaceutical Co's own Return-on-Tangible-Asset has ranged from 6.38 to 15.33 over the past decade. While the company's 10-year median is 10.18 vs. the industry median of 3.15, Ono Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ono Pharmaceutical Co's current Return-on-Tangible-Asset of 0.46% is 85.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ono Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ono Pharmaceutical Co's current Return-on-Tangible-Asset is 0.46%, which is 95% below median its own 10-year median of 10.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (OPHLF) is currently considered Fairly Valued. The stock's GF Value™ is $12.82, compared to a current price of $13.38 — trading 4.4% above its estimated fair value. The current Return-on-Tangible-Asset is 0.46%, which is 95% below median its 10-year median of 10.18 and 85.4% below the Drug Manufacturers industry median of 3.15. Ono Pharmaceutical Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Ono Pharmaceutical Co (OPHLF), the current Return-on-Tangible-Asset is 0.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (OPHLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of $13.38 is trading 4.4% above its estimated GF Value™ of $12.82.
GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.
Key valuation signals for OPHLF:
Return-on-Tangible-Asset: 0.46% (95% below median its 10-year median of 10.18)
GF Value™: $12.82 vs. price of $13.38 (4.4% above fair value)
Industry Position: 85.4% below the Drug Manufacturers median (#216 of 1007)
No single metric tells the full story. See the OPHLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
79GF Score
Get the complete analysis for OPHLF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPHLF has been successfully added to your 
